Hong Kong's Niche Stocks Split on Profitability: Blue Moon Dividend Scrutiny, Junshi's 45% Revenue Jump

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Hong Kong's small-cap stocks are revealing stark contrasts in their latest financial disclosures. Blue Moon Group (6993.HK) faces questions after distributing nearly HKD 2 billion in dividends during a period of cumulative losses totaling HKD 1.27 billion from 2024 through mid-2026. The cash payout, largely funded by IPO proceeds, saw approximately HKD 1.47 billion flow to controlling shareholder Pan Dong's family, reducing cash reserves from over HKD 10.9 billion in 2020 to HKD 2.837 billion by mid-2026.

Biotech firms show more promising trends. Junshi Bio (1877.HK) reported a turnaround in H1 2026 with CNY 25.5 million in net profit compared to losses a year earlier, as revenue surged 45% year-on-year to CNY 170 million. Domestic sales of its flagship drug Toripalimab rose 36% to CNY 130 million. Meanwhile, Beihai Kangcheng (1228.HK) saw its 2025 revenue decline 41.27% to CNY 49.983 million, yet recently gained 5.4% in a single week amid broader biotech sector recovery.

Traditional sectors display mixed results. China Galaxy Securities (6881.HK) joined the "trillion-yuan asset club" with total assets exceeding CNY 1.06 trillion in H1 2026, posting 22.58% revenue growth. Zhejiang Shibao (1057.HK) achieved 31.76% revenue growth in 2025 but continues to trade at a 408% A/H share premium, reflecting persistent liquidity challenges. Yingheng Tech (1760.HK) reported a 9.5% revenue decline for 2025, though its subsidiary delivered over 10 million automotive electronic components annually.

Micro-cap stocks highlight operational constraints. China Castchen 81 (0810.HK) generated merely HKD 348,000 in 2025 revenue, while Wanma Holdings (6928.HK) reported SGD 3.0339 million in revenue for 2025, up 7.17% but remaining modest in scale. The two ETF products—FA Southern Ethereum (3068.HK) and GX03 Monthly Bond (3440.HK)—have shown limited activity with no recent product-specific developments reported.

Source: Global Report The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.